ERIC P. NEIBART, M.D.
To the editor: Conte and associates (1) report their results with reduced-dose intravenous pentamidine and inhaled pentamidine as therapy for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Several questions, however, are raised by their presentation. Clinical and objective criteria for failure, and progression of success are not clearly defined. The authors state four patients had repeat bronchoscopy and persistent organisms were seen. Were these the patients that had relapses? The authors state that 90% of evaluable patients had a satisfactory response to inhaled pentamidine. This statement appears to be questionable if three patients had progression of disease
NEIBART EP. Pneumocystis Pneumonia. Ann Intern Med. ;108:489–490. doi: 10.7326/0003-4819-108-3-489_2
Download citation file:
Published: Ann Intern Med. 1988;108(3):489-490.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use